本帖最后由 老马 于 2012-1-13 21:20 编辑
- b, |2 `6 J/ D7 j
" y7 g5 N- B, Z# ]1 @爱必妥和阿瓦斯丁的比较. Q L$ v, n$ T+ z0 X) s
& [' Q% c. e9 g) X" W" t6 |http://cancergrace.org/lung/2008/08/30/bms099-os-neg/& r# k# J8 a: V7 n% S2 t
, b2 `: ^" D$ O
) h" W/ Z& I$ j9 K+ [$ H& S4 D* whttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 i8 x$ ?& W" ~. j/ P9 u, ?
==================================================
' W/ M, T- c. h; L9 i5 @2 @% xOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 s! ^ }: j- T% X. L+ \4 dPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 s* W! Z! J ?) Z' W& \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.% I3 X5 T4 r6 j: s
|